The delisting appeal creates a binary event: if the Panel denies continued listing, JUNS will be forced to trade OTC, likely triggering a severe price decline and loss of institutional access. The recent capital raise at a premium to market suggests some investor support, but the company's fundamentals remain precarious. Monitor for the hearing date and any Panel decision; a denial would be catastrophic, while a temporary stay could provide a short-term reprieve.
Price Chart
Executive Summary
Jupiter Neurosciences received a delisting notice from Nasdaq on August 27, 2026, for failing to maintain the minimum $35 million market value of listed securities (Rule 5550(b)(2)) after a 180-day cure period expired on August 25, 2026. The company intends to appeal the determination to a Nasdaq Hearings Panel, which will stay any suspension pending the hearing. Separately, the company regained compliance with the $1.00 minimum bid price rule (Rule 5550(a)(2)) on August 26, 2026, after 10 consecutive business days above that threshold. The delisting risk, combined with a recent dilutive capital raise of ~$1.74 million just 4 days prior, creates severe existential uncertainty for this $4M market cap clinical-stage biotech.
Key Facts
- Nasdaq notified Jupiter Neurosciences on August 27, 2026, of its determination to delist the company's common stock from the Nasdaq Capital Market.
- The delisting is due to failure to maintain the minimum $35,000,000 market value of listed securities (Rule 5550(b)(2)) after a 180-day cure period that expired on August 25, 2026.
- The company intends to appeal the delisting determination by requesting a hearing before the Nasdaq Hearings Panel, which will stay any further action pending the final determination.
- On August 26, 2026, the company regained compliance with the $1.00 minimum bid price requirement (Rule 5550(a)(2)) after 10 consecutive business days above that threshold.
- This filing follows a dilutive registered direct offering of 307,692 shares at $6.50 per share, raising approximately $1.74 million in net proceeds, filed on August 24, 2026.
Financial Impact
Delisting would severely reduce institutional ownership and liquidity for a $4M market cap company. The company recently raised ~$1.74M in a dilutive offering, but its cash runway is insufficient to fund operations for the next twelve months per the prior offering analysis.
Risk Factors
- Nasdaq Hearings Panel may deny the appeal, leading to immediate delisting and OTC trading with severely reduced liquidity.
- Even if the appeal is granted, the company may fail to regain compliance with the market value requirement within any extended cure period.
- The company's cash position is insufficient to fund operations for the next twelve months, creating a going-concern risk that could further impair Nasdaq compliance.
- Regaining bid price compliance does not resolve the market value deficiency, and the stock price could fall again, triggering additional listing issues.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-040577 |
| Document: 0001493152-26-040577-index.html | 0001493152-26-040577 |
| Document: 0001493152-26-040577.txt | 0001493152-26-040577 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 24, 2026 4w ago | S-3 | $2.67 $2.55 | ▲ +4.49% | ▲ +4.27% | $2.72 (−1.78%) |
Sep 22, 2026 4w ago | SC 13G | $2.98 $2.58 | ▼ −13.42% | ▼ −12.24% | $2.72 (−8.81%) |
Aug 28, 2026 8w ago | 8-K | $3.54 $3.08 | ▲ +12.99% | ▲ +12.85% | $2.72 (+23.24%) |
Aug 27, 2026 8w ago | 8-K | $4.89 $3.26 | ▲ +33.33% | ▲ +33.60% | $2.72 (+44.43%) |
Aug 24, 2026 8w ago | 8-K | $5.17 $3.35 | ▲ +35.20% | ▲ +34.66% | $2.72 (+47.44%) |
Aug 24, 2026 9w ago | 8-K | $5.66 $3.54 | ▲ +37.46% | ▲ +37.92% | $2.72 (+51.99%) |
Aug 24, 2026 9w ago | 424B5 | $5.66 $3.54 | ▲ +37.46% | ▲ +37.92% | $2.72 (+51.99%) |
Jul 27, 2026 13w ago | 8-K | $0.1135 $0.1000 | ▲ +11.89% | ▲ +14.41% | $2.72 (−2294.19%) |
Jul 21, 2026 13w ago | Press Release | $0.1697 $0.1097 | ▼ −35.36% | ▼ −34.36% | $2.72 (+1501.30%) |
Jul 8, 2026 15w ago | EFFECT | $0.1928 $0.1785 | ▲ +7.42% | ▲ +8.68% | $2.72 (−1309.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers